Lixiana is a once-daily selective Factor Xa inhibitor and is the fourth entrant in a relatively new category of novel oral anticoagulants (NOACs) that offer advantages over older drugs such as ...

with low potential of interaction with concomitant drugs.” Lixiana – sold as Savaysa in the US – was the fourth NOAC to reach the market in 2011 and is still a critical product for Daiichi ...